Do you have general questions about lung cancer? Post them here! We will reply with links and resources. This forum & site are NOT substitutes for professional medical advice. Please read all site disclaimers and consult your treating doctor about everything you read on the internet.
Hello to all of you. My name is Stacy and I'm 39. Sadly, we are all here for the same reason...the need for support from those who truly understand. I am reaching out for support because my mom, Susan 56yo, was diagnosed with lung cancer and multiple bone mets in March 2016. She has went through radiation to her skull, hip, sacrum and pubis bone. The pubis bone is now fractured. She also completed 4 rounds of chemo. Drugs were Carboplatin, Taxol and Avastin. She goes back for another PET scan this Thursday. Her health has declined severely since her diagnosis. I'm scared, depressed, confused, angry...you name it. I am her primary caregiver as most of our family is already in Heaven. How is everyone coping with their situations? I'm having a very difficult time accepting this. Any advice?
Sent from my iPhone using Tapatalk
On August 17, LUNGevity hosted a webinar with Dr. Julie Brahmer to discuss recent clinical trials in immunotherapy drugs. These trials have stimulated a lot of discussion in the lung cancer community. The webinar was moderated by LUNGevity's Vice President of Support & Surivivorship, Katie Brown.
Dr. Julie Brahmer is an immunotherapy expert at Johns Hopkins and a member of LUNGevity Scientific Advisory Board. Dr. Brahmer is an expert in the use of immunotherapies to treat lung cancer. She has spearheaded numerous clinical trials for the immunotherapy of lung cancer, including the pioneering trial that led to the approval of nivolumab in the second-line setting for advanced-stage lung cancer. Dr. Brahmer is the director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center. She is also a member of LUNGevity’s Scientific Advisory Board.
To listen to the webinar and to read the follow-up blog written by LUNGevity's Director of Science Communications, Dr. Upal Basu Roy, please click here.